Conquering Diseases

Study Of An Investigational Drug Combination For Recurring Platinum Resistant Ovarian Cancer


Seeking women whose ovarian cancer has returned following treatment for a study adding an investigational drug to the usual chemotherapy to see if it is better, the same or worse at extending life than the usual treatment alone.


Participants in this trial will be randomly assigned to receive either the investigational drug with one standard chemotherpay drug, the investigational drug with two standard chemotherapy drugs, or the usual chemotherapy with two chemotherapy drugs. Participants will be asked to complete quality of life questionnaires and come for follow-up office visits every 3 months for 2 years, and then every 6 months for 3 years.

What we're hoping for

We are studying if adding an investigational drug to the usual chemotherapy for platinum-resistant ovarian cancer that has recurred is better, the same, or worse than the usual chemotherapy at extending the life of participants by at least 6 months.

Additional Information Identifier: NCT02839707

 Principal Investigator

Susan  Zweizig, MD

UMass Memorial Health Care

 Study Contact

The Cancer  Research Office



UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655